Therefore, this study aimed to investigate whether BRD4 is one of the major contributors to the invasion-prone phenotype of NSCLC, and define the protein as a suitable candidate for therapeutic agents of NSCLC patients. Here, BRD4 is linked to non-small cell lung carcinoma.